10309-44-1Relevant articles and documents
Combining Palladium and Chiral Organocatalysis for the Enantioselective Deconjugative Allylation of Enals via Dienamine Intermediates
Hu, Guang,Brenner-Moyer, Stacey E.
, p. 866 - 873 (2022/01/04)
A catalytic enantioselective deconjugative allylation of enals is reported. A variety of enals underwent this transformation in high yield and ee, and products can be readily transformed into γ-allyl enals via a Cope rearrangement without erosion of ee. This transformation was used to install the quaternary stereocenter in (S)-bakuchiol, enabling completion of a concise formal synthesis.
Synthesis of Chiral Tertiary Boronic Esters: Phosphonate-Directed Catalytic Asymmetric Hydroboration of Trisubstituted Alkenes
Chakrabarty, Suman,Takacs, James M.
, p. 6066 - 6069 (2017/05/09)
Highly enantioselective rhodium-catalyzed hydroboration of allylic phosphonates by pinacolborane affords chiral tertiary boronic esters. The β-borylated phosphonates are readily converted to chiral β- and γ-hydroxyphosphonates and aminophosphonates and to phosphonates bearing a quaternary carbon stereocenter. The utility of the latter is illustrated by the synthesis of (S)-(+)-bakuchiol methyl ether.
Anti-proliferative evaluation of monoterpene derivatives against leukemia
Gautam, Lekh Nath,Ling, Taotao,Lang, Walter,Rivas, Fatima
supporting information, p. 75 - 80 (2016/03/01)
The cure rate of pediatric acute lymphoblastic leukemia (ALL) has significantly improved in the past thirty years, however not all patient cohorts respond well to current chemotherapy regimens. Among the high risk patient cohort is infants with MLL-rearranged (MLL-r) B-ALL, which remains dismal with an overall survival rate 35%. Our program is interested in identifying new molecular scaffolds to better understand the underlying mechanisms and ultimately provide new targeted treatments. Based on a phenotypic screen, phenolic natural products were identified as promising scaffolds for further chemical evaluation. Herein we disclose the effects of a potent anti-proliferative compound 31 against human ALL leukemia cellular models.